Exact Mass: 313.1889132

Exact Mass Matches: 313.1889132

Found 401 metabolites which its exact mass value is equals to given mass value 313.1889132, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Armepavine

Phenol, 4-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)-, (R)-

C19H23NO3 (313.16778480000005)


Armepavine is a member of isoquinolines. (-)-Armepavine is a natural product found in Berberis integerrima, Aconitum variegatum, and other organisms with data available. Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades[1]. Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades[1].

   

Ethylmorphine

(1S,5R,13R,14S,17R)-10-ethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraen-14-ol

C19H23NO3 (313.16778480000005)


A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products). R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants > R05DA - Opium alkaloids and derivatives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents > D000700 - Analgesics S - Sensory organs > S01 - Ophthalmologicals

   

Heliotrine

9-Heliotrylheliotridine

C16H27NO5 (313.1889132)


Origin: Plant; SubCategory_DNP: Alkaloids derived from ornithine, Pyrrolizidine alkaloids CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2319 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 120 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 140 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 160 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 170 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 130 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 110 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 100 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 150

   

(+)-Erysotrine

(1S,16R)-4,5,16-trimethoxy-10-azatetracyclo[8.7.0.0¹,¹³.0²,⁷]heptadeca-2,4,6,12,14-pentaene

C19H23NO3 (313.16778480000005)


(+)-Erysotrine is found in green vegetables. (+)-Erysotrine is an alkaloid from a wide range of Erythrina species including Erythrina abyssinica, Erythrina arborescens, Erythrina atitlanensis, Erythrina blakei, Erythrina caffra, Erythrina coralloides, Erythrina crista-galli, Erythrina flabelliformis, Erythrina folkersii, Erythrina fusca (gallito), Erythrina goldmanii, Erythrina guatemalensis, Erythrina herbacea, Erythrina lithosperma, Erythrina livingstoniana, Erythrina macrophylla, Erythrina mulungu, Erythrina oliviae, Erythrina poeppigiana, Erythrina senegalensis, Erythrina steyermarkii, Erythrina suberosa, Erythrina tajumulcensis, Erythrina variegata and Erythrina zeher

   
   

3-Methoxyestra-1,3,5(10)-trien-16-oximino-17-one

3-Methoxyestra-1,3,5(10)-triene-16,17-dione 16-oxime; 3-Methoxyestra-1,3,5(10)-trien-16-oximino-17-one

C19H23NO3 (313.16778480000005)


   

6-O-Methylcodeine

10,14-dimethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraene

C19H23NO3 (313.16778480000005)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids 6-O-Methylcodeine is a minor alkaloid of Papaver somniferum (opium poppy

   

9-Decenoylcarnitine

3-(dec-9-enoyloxy)-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


9-Decenoylcarnitine is an acylcarnitine. More specifically, it is an 9-decenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 9-decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

Reboxetine

(+)-(2S)-2-((S)-(2-Ethoxyphenoxy)phenylmethyl)morpholine

C19H23NO3 (313.16778480000005)


Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

   

(4Z)-Decenoylcarnitine

3-[(4Z)-Dec-4-enoyloxy]-4-(trimethylammonio)butanoic acid

C17H31NO4 (313.2252966)


(4Z)-Decenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z)-decenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z)-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4Z)-decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (4Z)-decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

cis-4-Decenoyl carnitine

CIS-4-DECENOYL CARNITINE

C17H31NO4 (313.2252966)


cis-4-Decenoyl carnitine is an acylcarnitine. More specifically, it is an cis-4-decenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. cis-4-Decenoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine cis-4-Decenoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular cis-4-Decenoyl carnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6E)-8-Methylnon-6-enoylcarnitine

3-[(8-methylnon-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


(6E)-8-Methylnon-6-enoylcarnitine is an acylcarnitine. More specifically, it is an (6E)-8-methylnon-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E)-8-Methylnon-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6E)-8-Methylnon-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,4-dimethylidenehexanedioylcarnitine

3-[(5-carboxy-3,4-dimethylidenepentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H23NO6 (313.1525298)


3,4-dimethylidenehexanedioylcarnitine is an acylcarnitine. More specifically, it is an 3,4-dimethylidenehexanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-dimethylidenehexanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-dimethylidenehexanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Decenoylcarnitine

3-(dec-3-enoyloxy)-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


3-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 3-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Decenoylcarnitine

3-(dec-6-enoyloxy)-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


6-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 6-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Decenoylcarnitine

3-(dec-7-enoyloxy)-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


7-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 7-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Decenoylcarnitine

3-(dec-5-enoyloxy)-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


5-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 5-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Decenoylcarnitine

3-(dec-2-enoyloxy)-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


2-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 2-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(8Z)-Decenoylcarnitine

3-(dec-8-enoyloxy)-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


(8Z)-Decenoylcarnitine is an acylcarnitine. More specifically, it is an (8Z)-dec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z)-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (8Z)-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (8Z)-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octa-3,5-dienedioylcarnitine

3-[(7-Carboxyhepta-3,5-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C15H23NO6 (313.1525298)


Octa-3,5-dienedioylcarnitine is an acylcarnitine. More specifically, it is an octa-3,5-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-3,5-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-3,5-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octa-2,6-dienedioylcarnitine

3-[(7-Carboxyhepta-2,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C15H23NO6 (313.1525298)


Octa-2,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an octa-2,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-2,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-2,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2Z,4Z)-Octa-2,4-dienedioylcarnitine

(2Z,4Z)-Octa-2,4-dienedioylcarnitine

C15H23NO6 (313.1525298)


(2Z,4Z)-octa-2,4-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (2Z,4Z)-octa-2,4-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z,4Z)-octa-2,4-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z,4Z)-octa-2,4-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octa-3,6-dienedioylcarnitine

3-[(7-Carboxyhepta-3,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C15H23NO6 (313.1525298)


Octa-3,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an octa-3,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-3,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-3,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxynona-4,7-dienoylcarnitine

3-[(3-hydroxynona-4,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H27NO5 (313.1889132)


3-hydroxynona-4,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxynona-4,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxynona-4,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxynona-4,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxynona-5,7-dienoylcarnitine

3-[(3-hydroxynona-5,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H27NO5 (313.1889132)


3-hydroxynona-5,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxynona-5,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxynona-5,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxynona-5,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxynona-4,6-dienoylcarnitine

3-[(3-Hydroxynona-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H27NO5 (313.1889132)


3-hydroxynona-4,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxynona-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxynona-4,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxynona-4,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(-)-Armepavine

4-[(6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]phenol

C19H23NO3 (313.16778480000005)


   

(1R,9S,10R)-17-(Cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol

(1R,9S,10R)-17-(Cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol

C20H27NO2 (313.2041682)


   

alpha-(Dimethylaminomethyl)-2-(3-ethyl-5-methyl-4-isoxazolyl)-1H-indole-3-methanol

alpha-(Dimethylaminomethyl)-2-(3-ethyl-5-methyl-4-isoxazolyl)-1H-indole-3-methanol

C18H23N3O2 (313.1790178)


   

10-(2-(Diethylamino)propyl)-10H-pyrido(3,2-b)(1,4)benzothiazine

diethyl(1-{9-thia-2,4-diazatricyclo[8.4.0.0^{3,8}]tetradeca-1(14),3(8),4,6,10,12-hexaen-2-yl}propan-2-yl)amine

C18H23N3S (313.16125980000004)


   

Decenoylcarnitine

3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tridec-5-enoate

C17H31NO4 (313.2252966)


   

Gardiquimod

1-{4-amino-2-[(ethylamino)methyl]-1H-imidazo[4,5-c]quinolin-1-yl}-2-methylpropan-2-ol

C17H23N5O (313.1902508)


   

Heliotron

(1-Hydroxy-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl)methyl 2-hydroxy-3-methoxy-2-(propan-2-yl)butanoic acid

C16H27NO5 (313.1889132)


   

Mavoglurant

methyl 4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate

C19H23NO3 (313.16778480000005)


   

Myofedrin

3-[(1-hydroxy-1-phenylpropan-2-yl)amino]-1-(3-methoxyphenyl)propan-1-one

C19H23NO3 (313.16778480000005)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents

   

Norethindrone oxime

14-ethynyl-5-(hydroxyimino)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-ol

C20H27NO2 (313.2041682)


   

Ricasetron

3,3-Dimethyl-N-{8-methyl-8-azabicyclo[3.2.1]octan-3-yl}-2,3-dihydro-1H-indole-1-carboximidate

C19H27N3O (313.2154012)


   

Sematilide

N-[2-(Diethylamino)ethyl]-4-methanesulphonamidobenzamide

C14H23N3O3S (313.1460048)


   
   

1-Methyl-2-(9-oxodecyl)quinolin-4-one

1-Methyl-2-(9-oxodecyl)quinolin-4-one

C20H27NO2 (313.2041682)


   
   

Dogo base

2a-Hydroxynominine

C20H27NO2 (313.2041682)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

1-Methyl-2-(9-oxodecyl)quinoline-4(1H)-one

1-Methyl-2-(9-oxodecyl)quinoline-4(1H)-one

C20H27NO2 (313.2041682)


   

5,6,8,9-tetrahydro-3,12-dimethoxy-7-methyl-dibenzazonin-2-ol|5,6,8,9-tetrahydro-3,12-dimethoxy-7-methyl-dibenz[d,f]azonin-2-ol|Laurifinin|laurifinine

5,6,8,9-tetrahydro-3,12-dimethoxy-7-methyl-dibenzazonin-2-ol|5,6,8,9-tetrahydro-3,12-dimethoxy-7-methyl-dibenz[d,f]azonin-2-ol|Laurifinin|laurifinine

C19H23NO3 (313.16778480000005)


   
   

7,8-Dimethoxy-2-methyl-1-(4-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline

7,8-Dimethoxy-2-methyl-1-(4-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline

C19H23NO3 (313.16778480000005)


   
   
   
   
   
   
   

retronecine (S)-2-hydroxy-2-((S)-1-hydroxyethyl)-4-methyl-pentanoyl ester|Retronecine 2S-hydroxy-2S-(1S-hydroxyethyl)-4-methylpentanoyl ester

retronecine (S)-2-hydroxy-2-((S)-1-hydroxyethyl)-4-methyl-pentanoyl ester|Retronecine 2S-hydroxy-2S-(1S-hydroxyethyl)-4-methylpentanoyl ester

C16H27NO5 (313.1889132)


   

15,16-methanediyldioxy-3beta-methoxy-11a-homo-erythrin-1(6)-ene|3-epi-epischellhammericine|3-epi-schelhammereicine|3-epi-Schelhammericin|3-epi-schelhammericine|3-Epischelhammericine

15,16-methanediyldioxy-3beta-methoxy-11a-homo-erythrin-1(6)-ene|3-epi-epischellhammericine|3-epi-schelhammereicine|3-epi-Schelhammericin|3-epi-schelhammericine|3-Epischelhammericine

C19H23NO3 (313.16778480000005)


   
   

(+-)Petalinjodid|1-(4-Methoxy-benzyl)-1,2,3,4-tetrahydro-7-methoxy-2-methyl-8-isochinolinol|1-(4-Methoxy-benzyl)-8-hydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-isochinolin|1-(4-Methoxybenzyl)-7-methoxy-2-methyl-1,2,3,4-tetrahydro-8-isochinolinol|7-methoxy-1-(4-methoxy-benzyl)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-8-ol|Gorchacoine|Gortschakoin|Petalinjodid

(+-)Petalinjodid|1-(4-Methoxy-benzyl)-1,2,3,4-tetrahydro-7-methoxy-2-methyl-8-isochinolinol|1-(4-Methoxy-benzyl)-8-hydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-isochinolin|1-(4-Methoxybenzyl)-7-methoxy-2-methyl-1,2,3,4-tetrahydro-8-isochinolinol|7-methoxy-1-(4-methoxy-benzyl)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-8-ol|Gorchacoine|Gortschakoin|Petalinjodid

C19H23NO3 (313.16778480000005)


   
   
   

1-ethenamino-7-(5-oxohex-1-ynyl)phenanthrene

1-ethenamino-7-(5-oxohex-1-ynyl)phenanthrene

C22H19NO (313.14665640000004)


   

Retronecine 9-O-curassavate

Retronecine 9-O-curassavate

C16H27NO5 (313.1889132)


   

7-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylhepta-2,4-dien-1-one

7-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylhepta-2,4-dien-1-one

C19H23NO3 (313.16778480000005)


   

(n-Undecanon-10)-2-chinolon-4|2-(10-oxo-undecyl)-1H-quinolin-4-one|2-(10-Oxoundecyl)-4(1H)-quinolinone

(n-Undecanon-10)-2-chinolon-4|2-(10-oxo-undecyl)-1H-quinolin-4-one|2-(10-Oxoundecyl)-4(1H)-quinolinone

C20H27NO2 (313.2041682)


   
   
   
   
   
   
   

(2E,6E)-7-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one|4,5-dihydropiperettine|pipersintenamide

(2E,6E)-7-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one|4,5-dihydropiperettine|pipersintenamide

C19H23NO3 (313.16778480000005)


   
   
   
   
   
   
   
   

alpha-Codeimethine

alpha-Codeimethine

C19H23NO3 (313.16778480000005)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.481 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.478

   
   

Maprotiline Hydrochloride

Maprotiline Hydrochloride

C20H24ClN (313.15971740000003)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent > C94727 - Tricyclic Antidepressant D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators

   
   

ethylmorphine

ethylmorphine

C19H23NO3 (313.16778480000005)


R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants > R05DA - Opium alkaloids and derivatives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents > D000700 - Analgesics S - Sensory organs > S01 - Ophthalmologicals

   
   
   
   
   
   
   

PC(O-2:0/O-2:0)

3,5,9-Trioxa-4-phosphaundecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (R)-

C12H28NO6P (313.16541580000006)


   

PC(O-4:0/0:0)[U]

3,5,9-Trioxa-4-phosphatridecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (1)-

C12H28NO6P (313.16541580000006)


   

Reboxetine

(2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine

C19H23NO3 (313.16778480000005)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C185721 - Norepinephrine Reuptake Inhibitor C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators

   

Codeine methyl ether

10,14-dimethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene

C19H23NO3 (313.16778480000005)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids

   

CAR 10:1

(Z)-dec-4-enoylcarnitine;3-[(4Z)-dec-4-enoyloxy]-4-(trimethylammonio)butanoate;cis-4-decenoylcarnitine

C17H31NO4 (313.2252966)


   

3O-C12-HTL

N-(3-oxo-dodecanoyl)-homoserine thiolactone

C16H27NO3S (313.17115520000004)


   

tert-Butyl 4-(isoquinolin-3-yl)piperazine-1-carboxylate

tert-Butyl 4-(isoquinolin-3-yl)piperazine-1-carboxylate

C18H23N3O2 (313.1790178)


   

4-[5-(4-butylphenyl)pyrimidin-2-yl]benzonitrile

4-[5-(4-butylphenyl)pyrimidin-2-yl]benzonitrile

C21H19N3 (313.15788940000004)


   

N,N,N-[(Vinylsilanetriyl)tris(oxy)]tri(2-butanimine)

N,N,N-[(Vinylsilanetriyl)tris(oxy)]tri(2-butanimine)

C14H27N3O3Si (313.18215919999994)


   

H-Leu-Gly-βNA

L-leucylglycine 2-naphthylamide

C18H23N3O2 (313.1790178)


   

N-Desmethylterbinafine hydrochloride

N-Desmethylterbinafine hydrochloride

C20H24ClN (313.15971740000003)


   
   

Sematilide

Sematilide

C14H23N3O3S (313.1460048)


C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(1-piperazinyl)

3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(1-piperazinyl)

C17H19N3O3 (313.1426344)


   

3-AMINO-N,N-DIETHYL-4-MORPHOLIN-4-YL-BENZENESULFONAMIDE

3-AMINO-N,N-DIETHYL-4-MORPHOLIN-4-YL-BENZENESULFONAMIDE

C14H23N3O3S (313.1460048)


   

tert-butyl 4-(4-amino-2,6-difluorophenyl)piperazine-1-carboxylate

tert-butyl 4-(4-amino-2,6-difluorophenyl)piperazine-1-carboxylate

C15H21F2N3O2 (313.160175)


   

Oxilorphan

Oxilorphan

C20H27NO2 (313.2041682)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist

   

ethyl 1-(6-formylquinazolin-4-yl)piperidine-3-carboxylate

ethyl 1-(6-formylquinazolin-4-yl)piperidine-3-carboxylate

C17H19N3O3 (313.1426344)


   

1-BOC-3-(3-MORPHOLIN-4-YL-PROPYLAMINO)-PYRROLIDINE

1-BOC-3-(3-MORPHOLIN-4-YL-PROPYLAMINO)-PYRROLIDINE

C16H31N3O3 (313.23652960000004)


   

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate

C15H23NO6 (313.1525298)


   

1-(4-Methoxyphenyl)-4-(4-nitrophenyl)piperazine

1-(4-Methoxyphenyl)-4-(4-nitrophenyl)piperazine

C17H19N3O3 (313.1426344)


   

2H-Pyrrol-2-one, 4-acetyl-5-cyclohexyl-1,5-dihydro-3-hydroxy-1-(4-methylphenyl)-

2H-Pyrrol-2-one, 4-acetyl-5-cyclohexyl-1,5-dihydro-3-hydroxy-1-(4-methylphenyl)-

C19H23NO3 (313.16778480000005)


   

2H-Pyrrol-2-one, 4-acetyl-5-cyclohexyl-1,5-dihydro-3-hydroxy-1-(4-methylphenyl)-, (5R)-

2H-Pyrrol-2-one, 4-acetyl-5-cyclohexyl-1,5-dihydro-3-hydroxy-1-(4-methylphenyl)-, (5R)-

C19H23NO3 (313.16778480000005)


   

ethyl 1-(6-formylquinazolin-4-yl)piperidine-4-carboxylate

ethyl 1-(6-formylquinazolin-4-yl)piperidine-4-carboxylate

C17H19N3O3 (313.1426344)


   

7-(3-azaspiro[5.5]undecan-9-yloxy)chromen-2-one

7-(3-azaspiro[5.5]undecan-9-yloxy)chromen-2-one

C19H23NO3 (313.16778480000005)


   

6-(3-azaspiro[5.5]undecan-9-yloxy)chromen-2-one

6-(3-azaspiro[5.5]undecan-9-yloxy)chromen-2-one

C19H23NO3 (313.16778480000005)


   

5-METHYL-N2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYL)PYRIMIDINE-2,4-DIAMINE

5-METHYL-N2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYL)PYRIMIDINE-2,4-DIAMINE

C17H23N5O (313.1902508)


   

Xenysalate

2-(diethylamino)ethyl 2-hydroxy-3-phenylbenzoate

C19H23NO3 (313.16778480000005)


D - Dermatologicals > D11 - Other dermatological preparations > D11A - Other dermatological preparations > D11AC - Medicated shampoos C78284 - Agent Affecting Integumentary System > C29700 - Astringent

   

(17alpha)-17-hydroxy-3-oxoandrost-4-ene-17-carbonitrile

(17alpha)-17-hydroxy-3-oxoandrost-4-ene-17-carbonitrile

C20H27NO2 (313.2041682)


   

Fenalcomine

Fenalcomine

C20H27NO2 (313.2041682)


C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent

   

Benzenemethanaminium,N,N,N-tripropyl-, bromide (1:1)

Benzenemethanaminium,N,N,N-tripropyl-, bromide (1:1)

C16H28BrN (313.14049880000005)


   
   

1-(4-methoxyphenyl)-2-[2-(4-methoxyphenyl)ethylamino]propan-1-one

1-(4-methoxyphenyl)-2-[2-(4-methoxyphenyl)ethylamino]propan-1-one

C19H23NO3 (313.16778480000005)


   

Bis(4-methoxyphenyl)[(2S)-2-pyrrolidinyl]methanol

Bis(4-methoxyphenyl)[(2S)-2-pyrrolidinyl]methanol

C19H23NO3 (313.16778480000005)


   

Light Stabilizer 622

Light Stabilizer 622

C17H31NO4 (313.2252966)


   

1-Naphthyl(1-propyl-1H-indol-3-yl)methanone

1-Naphthyl(1-propyl-1H-indol-3-yl)methanone

C22H19NO (313.14665640000004)


   

N-[2-Isopropylthiazol-4-ylmethyl(methyl)carbamoyl]-L-valine

N-[2-Isopropylthiazol-4-ylmethyl(methyl)carbamoyl]-L-valine

C14H23N3O3S (313.1460048)


   

Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-(2-methylphenyl)-1-piperazinyl]

Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-(2-methylphenyl)-1-piperazinyl]

C18H23N3O2 (313.1790178)


   

Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(2,3-dimethylphenyl)-1-piperazinyl]-

Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(2,3-dimethylphenyl)-1-piperazinyl]-

C18H23N3O2 (313.1790178)


   

Vetrabutine

Dmophebumine

C20H27NO2 (313.2041682)


C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

TERT-BUTYL 4-(ISOQUINOLIN-5-YL)PIPERAZINE-1-CARBOXYLATE

TERT-BUTYL 4-(ISOQUINOLIN-5-YL)PIPERAZINE-1-CARBOXYLATE

C18H23N3O2 (313.1790178)


   

2,2-dimethyl-N-[(4-propan-2-yloxyphenyl)methyl]oxan-4-amine,hydrochloride

2,2-dimethyl-N-[(4-propan-2-yloxyphenyl)methyl]oxan-4-amine,hydrochloride

C17H28ClNO2 (313.18084580000004)


   

tert-Butyl 3-(2-(tert-butoxy)-2-oxoethyl)-4-oxopiperidine-1-carboxylate

tert-Butyl 3-(2-(tert-butoxy)-2-oxoethyl)-4-oxopiperidine-1-carboxylate

C16H27NO5 (313.1889132)


   

(4R)-2-Methyl-4,5,5-triphenyl-1,3,2-oxazaborolidine

(4R)-2-Methyl-4,5,5-triphenyl-1,3,2-oxazaborolidine

C21H20BNO (313.163786)


   

ethyl 2-(dibenzylamino)-3-hydroxypropanoate

ethyl 2-(dibenzylamino)-3-hydroxypropanoate

C19H23NO3 (313.16778480000005)


   

Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-(3-methylphenyl)-1-piperazinyl]

Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-(3-methylphenyl)-1-piperazinyl]

C18H23N3O2 (313.1790178)


   

2H,4H-[1,3]Dioxolo[4,5-h]indolo[7a,1-a][2]benzazepine,1,5,6,12,13,14-hexahydro-13-methoxy-, (11bS,13S)-

2H,4H-[1,3]Dioxolo[4,5-h]indolo[7a,1-a][2]benzazepine,1,5,6,12,13,14-hexahydro-13-methoxy-, (11bS,13S)-

C19H23NO3 (313.16778480000005)


   

(S)-ethyl 2-(tert-butoxycarbonylamino)-5-oxonon-8-enoate

(S)-ethyl 2-(tert-butoxycarbonylamino)-5-oxonon-8-enoate

C16H27NO5 (313.1889132)


   

N-Dodecanoyl-4-hydroxy-L-proline

N-Dodecanoyl-4-hydroxy-L-proline

C17H31NO4 (313.2252966)


   

13-Ethyl-17-hydroxy-18,19-dinorpregn-5(10)-en-20-yn-3-one

13-Ethyl-17-hydroxy-18,19-dinorpregn-5(10)-en-20-yn-3-one

C21H29O2 (313.2167434)


   

3-(Dimethylamino)-1-(6-(3-methoxyphenyl)-7,7a-dihydroimidazo[2,1-b]oxazol-5-yl)prop-2-en-1-one

3-(Dimethylamino)-1-(6-(3-methoxyphenyl)-7,7a-dihydroimidazo[2,1-b]oxazol-5-yl)prop-2-en-1-one

C17H19N3O3 (313.1426344)


   

rac 5-Carboxy Desisopropyl Tolterodine

rac 5-Carboxy Desisopropyl Tolterodine

C19H23NO3 (313.16778480000005)


   

P-TOLYLTETRAZOLIUM RED

P-TOLYLTETRAZOLIUM RED

C20H17N4+ (313.1453142)


   

Venlafaxine hydrochloride

Venlafaxine hydrochloride

C17H28ClNO2 (313.18084580000004)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D049990 - Membrane Transport Modulators

   

Acecainide hydrochloride

N-AcetylprocainaMide hydrochloride

C15H24ClN3O2 (313.15569539999996)


C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C93038 - Cation Channel Blocker

   

BenzeneMethanol, 3-[5-[(1-Methyl-4-piperidinyl)Methoxy]-2-pyrimidinyl]-

BenzeneMethanol, 3-[5-[(1-Methyl-4-piperidinyl)Methoxy]-2-pyrimidinyl]-

C18H23N3O2 (313.1790178)


   

mavoglurant

mavoglurant

C19H23NO3 (313.16778480000005)


C78272 - Agent Affecting Nervous System Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease[1][1][2]. Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

   

4-Benzyloxy-2-piperidine-1-yl-pyrimidine-5-boronic acid

4-Benzyloxy-2-piperidine-1-yl-pyrimidine-5-boronic acid

C16H20BN3O3 (313.159764)


   

Amitriptyline Hydrochloride

Amitriptyline Hydrochloride

C20H24ClN (313.15971740000003)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent > C94727 - Tricyclic Antidepressant D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D049990 - Membrane Transport Modulators Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with Kis of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a Ki of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity[1][2][3].

   

N-cyclopentyl-5-(3,4-dimethoxyphenyl)-2-methylpyrimidin-4-amine

N-cyclopentyl-5-(3,4-dimethoxyphenyl)-2-methylpyrimidin-4-amine

C18H23N3O2 (313.1790178)


   

tert-butyl 4-(3-(ethoxycarbonyl)-2-oxopropyl)piperidine-1-carboxylate

tert-butyl 4-(3-(ethoxycarbonyl)-2-oxopropyl)piperidine-1-carboxylate

C16H27NO5 (313.1889132)


   

TERT-BUTYL 4-(ISOQUINOLIN-1-YL)PIPERAZINE-1-CARBOXYLATE

TERT-BUTYL 4-(ISOQUINOLIN-1-YL)PIPERAZINE-1-CARBOXYLATE

C18H23N3O2 (313.1790178)


   

4-(Cyclohexyliminomethyl)benzeneboronic acid pinacol ester

4-(Cyclohexyliminomethyl)benzeneboronic acid pinacol ester

C19H28BNO2 (313.2212978)


   

6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline

6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline

C19H23NO3 (313.16778480000005)


   

4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]piperidine,hydrochloride

4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]piperidine,hydrochloride

C14H25BClN3O2 (313.172825)


   

oxyfedrine

oxyfedrine

C19H23NO3 (313.16778480000005)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents

   

Irdabisant

Irdabisant

C18H23N3O2 (313.1790178)


C254 - Anti-Infective Agent Irdabisant (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist with Ki values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively. Irdabisant has relatively low inhibitory activity against hERG current with an IC50 of 13.8 μM. Irdabisant has cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant can be used to research schizophrenia or cognitive impairment[1][2].

   

7,8-Dihydro-6-hydroxymethyl-7-methyl-7-[2-phenylethyl]-pterin

7,8-Dihydro-6-hydroxymethyl-7-methyl-7-[2-phenylethyl]-pterin

C16H19N5O2 (313.15386739999997)


   
   

erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride

erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride

C14H24ClN5O (313.16692839999996)


D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D004791 - Enzyme Inhibitors

   

Indisetron

Indisetron

C17H23N5O (313.1902508)


C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist

   

7-Isoquinolinol, 1,2,3,4-tetrahydro-6-methoxy-1-((4-methoxyphenyl)methyl)-2-methyl-, (S)-

7-Isoquinolinol, 1,2,3,4-tetrahydro-6-methoxy-1-((4-methoxyphenyl)methyl)-2-methyl-, (S)-

C19H23NO3 (313.16778480000005)


   

5-(Dodecylthio)-1h-1,2,3-Triazole-4-Carboxylic Acid

5-(Dodecylthio)-1h-1,2,3-Triazole-4-Carboxylic Acid

C15H27N3O2S (313.1823882)


   

5-[(4-Aminocyclohexyl)amino]-7-(propan-2-ylamino)pyrazolo[1,5-A]pyrimidine-3-carbonitrile

5-[(4-Aminocyclohexyl)amino]-7-(propan-2-ylamino)pyrazolo[1,5-A]pyrimidine-3-carbonitrile

C16H23N7 (313.2014838)


   

5-tert-butyl-N-(2,3-dihydro-1-benzouran-5-ylmethyl)-2-methylpyrazole-3-carboxamide

5-tert-butyl-N-(2,3-dihydro-1-benzouran-5-ylmethyl)-2-methylpyrazole-3-carboxamide

C18H23N3O2 (313.1790178)


   

14-[2-(Dimethylamino)ethyl]-11-methoxy-15-oxatetracyclo[10.2.1.05,14.08,13]pentadeca-3,6,8(13),9,11-pentaen-2-ol

14-[2-(Dimethylamino)ethyl]-11-methoxy-15-oxatetracyclo[10.2.1.05,14.08,13]pentadeca-3,6,8(13),9,11-pentaen-2-ol

C19H23NO3 (313.16778480000005)


   

1-isopropyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

1-isopropyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

C16H19N5O2 (313.15386739999997)


   

(1R,9S,10R)-17-(Cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol

(1R,9S,10R)-17-(Cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol

C20H27NO2 (313.2041682)


   

[(8R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl 2-hydroxy-2-(1-methoxyethyl)-3-methylbutanoate

[(8R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl 2-hydroxy-2-(1-methoxyethyl)-3-methylbutanoate

C16H27NO5 (313.1889132)


   

9,10-Epoxy-18-hydroxystearate

9,10-Epoxy-18-hydroxystearate

C18H33O4- (313.2378718)


   

12,13-DiHOME(1-)

12,13-DiHOME(1-)

C18H33O4- (313.2378718)


A monounsaturated fatty acid anion that is the conjugate base of 12,13-DiHOME, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(8E,10S)-10-Hydroperoxy-8-octadecenoate

(8E,10S)-10-Hydroperoxy-8-octadecenoate

C18H33O4- (313.2378718)


An unsaturated fatty acid anion that is the conjugate base of (8E,10S)-10-hydroperoxy-8-octadecenoic acid, obtained by deprotonation of the carboxy group.

   

(1R,2R,5R,8R,9S,10R,11S)-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylate

(1R,2R,5R,8R,9S,10R,11S)-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylate

C19H21O4- (313.14397660000003)


   

(2S)-2-[(E)-[(2S)-2-amino-3-(4-hydroxyphenyl)propylidene]amino]-3-(4-hydroxyphenyl)propanal

(2S)-2-[(E)-[(2S)-2-amino-3-(4-hydroxyphenyl)propylidene]amino]-3-(4-hydroxyphenyl)propanal

C18H21N2O3+ (313.15520960000003)


   

5-Ethyl-3-imino-6-phenyl-phenanthridin-8-amine

5-Ethyl-3-imino-6-phenyl-phenanthridin-8-amine

C21H19N3 (313.15788940000004)


   

(2S)-2-[[(2E,6E)-7-carboxy-3-methylocta-2,6-dienyl]amino]pentanedioic acid

(2S)-2-[[(2E,6E)-7-carboxy-3-methylocta-2,6-dienyl]amino]pentanedioic acid

C15H23NO6 (313.1525298)


   

3-[(E)-dec-4-enoyl]oxy-4-(trimethylazaniumyl)butanoate

3-[(E)-dec-4-enoyl]oxy-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


   

3,4-dimethylidenehexanedioylcarnitine

3,4-dimethylidenehexanedioylcarnitine

C15H23NO6 (313.1525298)


   

(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tridec-5-enoate

(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tridec-5-enoate

C17H31NO4 (313.2252966)


   

2-Decenoyl carnitine

2-Decenoyl carnitine

C17H31NO4 (313.2252966)


   

Norethindrone oxime

Norethindrone oxime

C20H27NO2 (313.2041682)


   

3-Decenoylcarnitine

3-[(E)-dec-3-enoyl]oxy-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


3-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279 ). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review (PMID: 35710135 ), acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494 ). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 3-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392 ). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852 ) and familial mediterranean fever (PMID: 29900937 ). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279 ). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available (PMID: 35710135 ).

   

6-Decenoylcarnitine

6-Decenoylcarnitine

C17H31NO4 (313.2252966)


   

7-Decenoylcarnitine

7-Decenoylcarnitine

C17H31NO4 (313.2252966)


   

5-Decenoylcarnitine

5-Decenoylcarnitine

C17H31NO4 (313.2252966)


   

(8Z)-Decenoylcarnitine

(8Z)-Decenoylcarnitine

C17H31NO4 (313.2252966)


   

Octa-3,5-dienedioylcarnitine

Octa-3,5-dienedioylcarnitine

C15H23NO6 (313.1525298)


   

Octa-2,6-dienedioylcarnitine

Octa-2,6-dienedioylcarnitine

C15H23NO6 (313.1525298)


   

Octa-3,6-dienedioylcarnitine

Octa-3,6-dienedioylcarnitine

C15H23NO6 (313.1525298)


   

3-Hydroxynona-4,7-dienoylcarnitine

3-Hydroxynona-4,7-dienoylcarnitine

C16H27NO5 (313.1889132)


   

3-Hydroxynona-5,7-dienoylcarnitine

3-Hydroxynona-5,7-dienoylcarnitine

C16H27NO5 (313.1889132)


   

3-Hydroxynona-4,6-dienoylcarnitine

3-Hydroxynona-4,6-dienoylcarnitine

C16H27NO5 (313.1889132)


   

(6E)-8-Methylnon-6-enoylcarnitine

(6E)-8-Methylnon-6-enoylcarnitine

C17H31NO4 (313.2252966)


   

(2Z,4Z)-Octa-2,4-dienedioylcarnitine

(2Z,4Z)-Octa-2,4-dienedioylcarnitine

C15H23NO6 (313.1525298)


   

(3R)-3-[(Z)-dec-4-enoyl]oxy-4-(trimethylazaniumyl)butanoate

(3R)-3-[(Z)-dec-4-enoyl]oxy-4-(trimethylazaniumyl)butanoate

C17H31NO4 (313.2252966)


   

2-[(2-Ethoxyphenoxy)-phenylmethyl]morpholine

2-[(2-Ethoxyphenoxy)-phenylmethyl]morpholine

C19H23NO3 (313.16778480000005)


   

N-[(1-ethylpyrrolidin-2-yl)methyl]-8-fluoro-5H-pyrimido[5,4-b]indol-4-amine

N-[(1-ethylpyrrolidin-2-yl)methyl]-8-fluoro-5H-pyrimido[5,4-b]indol-4-amine

C17H20FN5 (313.1702652)


   

N-(2,4-dimethylphenyl)-4-[2-(2-furylmethylene)hydrazino]-4-oxobutanamide

N-(2,4-dimethylphenyl)-4-[2-(2-furylmethylene)hydrazino]-4-oxobutanamide

C17H19N3O3 (313.1426344)


   
   

Norajmaline(1+)

Norajmaline(1+)

C19H25N2O2+ (313.191593)


An organic cation obtained by protonation of the tertiary amino group of norajmaline; major structure at pH 7.3.

   
   

3-Butyl-5-(4-morpholinylmethyl)-2-oxo-3-oxolanecarboxylic acid ethyl ester

3-Butyl-5-(4-morpholinylmethyl)-2-oxo-3-oxolanecarboxylic acid ethyl ester

C16H27NO5 (313.1889132)


   
   

N,N-dimethyl-3-[(2-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)thio]-1-propanamine

N,N-dimethyl-3-[(2-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)thio]-1-propanamine

C18H23N3S (313.16125980000004)


   

10-hydroperoxy-8E-octadecenoate

10-hydroperoxy-8E-octadecenoate

C18H33O4- (313.2378718)


A hydroperoxy fatty acid anion resulting from the deprotonation of the carboxy group of 10-hydroperoxy-8E-octadecenoic acid. The major species at pH 7.3.

   

(12Z)-9,10-Dihydroxyoctadec-12-enoate

(12Z)-9,10-Dihydroxyoctadec-12-enoate

C18H33O4- (313.2378718)


   

9-hydroperoxy-10E-octadecenoate

9-hydroperoxy-10E-octadecenoate

C18H33O4- (313.2378718)


A hydroperoxy fatty acid anion resulting from the deprotonation of the carboxy group of 9-hydroperoxy-10E-octadecenoic acid. The major species at pH 7.3.

   

N-(6-Butyrylamino-pyridin-3-yl)-2-methoxy-benzamide

N-(6-Butyrylamino-pyridin-3-yl)-2-methoxy-benzamide

C17H19N3O3 (313.1426344)


   

1-cyclohexyl-N-(3-methylbutyl)-5-benzimidazolecarboxamide

1-cyclohexyl-N-(3-methylbutyl)-5-benzimidazolecarboxamide

C19H27N3O (313.2154012)


   

(9Z,12R)-12,18-dihydroxyoctadecenoate

(9Z,12R)-12,18-dihydroxyoctadecenoate

C18H33O4- (313.2378718)


A hydroxy fatty acid anion that is the conjugate base of (9Z,12R)-12,18-dihydroxyoctadecenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(9R,10S)-18-Hydroxy-9,10-epoxystearate

(9R,10S)-18-Hydroxy-9,10-epoxystearate

C18H33O4- (313.2378718)


   

3-[5-(4-Methylphenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acid

3-[5-(4-Methylphenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acid

C19H23NO3 (313.16778480000005)


   

[2-[(2,6-dimethyl-4-morpholinyl)-oxomethyl]phenyl]-(1H-imidazol-2-yl)methanone

[2-[(2,6-dimethyl-4-morpholinyl)-oxomethyl]phenyl]-(1H-imidazol-2-yl)methanone

C17H19N3O3 (313.1426344)


   

7-methyl-3-(4-morpholinyl)-1-(prop-2-enylamino)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

7-methyl-3-(4-morpholinyl)-1-(prop-2-enylamino)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

C17H23N5O (313.1902508)


   

1-(2-Fluorophenyl)-3-[2-(1-piperidinyl)phenyl]urea

1-(2-Fluorophenyl)-3-[2-(1-piperidinyl)phenyl]urea

C18H20FN3O (313.1590322)


   

(2R)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine

(2R)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine

C19H23NO3 (313.16778480000005)


   

1-(4-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone

1-(4-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone

C19H20FNO2 (313.1477992)


   

2-hydroxy-2-[(1R)-1-methoxyethyl]-3-methylbutanoic acid [(7S,8R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl ester

2-hydroxy-2-[(1R)-1-methoxyethyl]-3-methylbutanoic acid [(7S,8R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl ester

C16H27NO5 (313.1889132)


   

5,5-Diethyl-2-(2-hydroxyethylamino)-1,6-dihydrobenzo[h]quinazolin-4-one

5,5-Diethyl-2-(2-hydroxyethylamino)-1,6-dihydrobenzo[h]quinazolin-4-one

C18H23N3O2 (313.1790178)


   

(9S,10R)-9,10-epoxy-18-hydroxystearate

(9S,10R)-9,10-epoxy-18-hydroxystearate

C18H33O4- (313.2378718)


   

(2R,9Z)-2-hydroperoxyoctadecenoate

(2R,9Z)-2-hydroperoxyoctadecenoate

C18H33O4- (313.2378718)


   
   
   
   
   

3-Methoxyestra-1,3,5(10)-triene-16,17-dione 16-oxime

3-Methoxyestra-1,3,5(10)-triene-16,17-dione 16-oxime

C19H23NO3 (313.16778480000005)


   

1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol;hydron;chloride

1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol;hydron;chloride

C17H28ClNO2 (313.18084580000004)


   

1-[(1-Tert-butyl-5-tetrazolyl)-phenylmethyl]-4-methylpiperidine

1-[(1-Tert-butyl-5-tetrazolyl)-phenylmethyl]-4-methylpiperidine

C18H27N5 (313.2266342)


   

3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-cyclopropylpropanamide

3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-cyclopropylpropanamide

C18H23N3O2 (313.1790178)


   

4-(1-piperazinyl)-N,N-dipropyl-2-quinazolinamine

4-(1-piperazinyl)-N,N-dipropyl-2-quinazolinamine

C18H27N5 (313.2266342)


   
   
   

trans-Methoxymycolate

trans-Methoxymycolate

C18H33O4- (313.2378718)


   

9-cis-4-Oxoretinoate

9-cis-4-Oxoretinoate

C20H25O3- (313.18035999999995)


A retinoid anion that is the conjugate base of 9-cis-4-oxoretinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

15-deoxy-Delta(12,14)-prostaglandin J3(1-)

15-deoxy-Delta(12,14)-prostaglandin J3(1-)

C20H25O3- (313.18035999999995)


A prostaglandin carboxylic acid anion that is the conjugate base of 15-deoxy-Delta(12,14)-prostaglandin J3. obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

17-Hydroxy-9,10-epoxystearate

17-Hydroxy-9,10-epoxystearate

C18H33O4- (313.2378718)


   

(8R)-hydroperoxy-(9Z)-octadecenoate

(8R)-hydroperoxy-(9Z)-octadecenoate

C18H33O4- (313.2378718)


   

(10R)-hydroperoxy-(8E)-octadecenoate

(10R)-hydroperoxy-(8E)-octadecenoate

C18H33O4- (313.2378718)


   

1-(3-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone

1-(3-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone

C19H20FNO2 (313.1477992)


   

1-(2-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone

1-(2-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone

C19H20FNO2 (313.1477992)


   

(3-Butoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(3-Butoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C12H28NO6P (313.16541580000006)


   

2-Aminoethyl (3-heptoxy-2-hydroxypropyl) hydrogen phosphate

2-Aminoethyl (3-heptoxy-2-hydroxypropyl) hydrogen phosphate

C12H28NO6P (313.16541580000006)


   

9,10-Epoxy-18-hydroxyoctadecanoate

9,10-Epoxy-18-hydroxyoctadecanoate

C18H33O4 (313.2378718)


An omega-hydroxy fatty acid anion that is the conjugate base of 18-hydroxy-9,10-epoxyoctadecanoic acid arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

9-Decenoylcarnitine

9-Decenoylcarnitine

C17H31NO4 (313.2252966)


   

6-O-METHYLCODEINE

6-O-METHYLCODEINE

C19H23NO3 (313.16778480000005)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids

   

cis-4-Decenoylcarnitine

cis-4-Decenoylcarnitine

C17H31NO4 (313.2252966)


   

9,10-DiHOME(1-)

9,10-DiHOME(1-)

C18H33O4 (313.2378718)


A monounsaturated fatty acid anion that is the conjugate base of 9,10-DiHOME, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(9S,10R)-9,10-epoxy-18-hydroxyoctadecanoate

(9S,10R)-9,10-epoxy-18-hydroxyoctadecanoate

C18H33O4 (313.2378718)


A 9,10-epoxy-18-hydroxyoctadecanoate that is the conjugate base of (9S,10R)-9,10-epoxy-18-hydroxyoctadecanoic acid arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

O-decenoylcarnitine

O-decenoylcarnitine

C17H31NO4 (313.2252966)


An O-acylcarnitine in which the acyl group is specified as decenoyl (position of double bond not specified).

   

O-decenoyl-L-carnitine

O-decenoyl-L-carnitine

C17H31NO4 (313.2252966)


An O-acyl-L-carnitine that is L-carnitine having decenoyl group as the acyl substituent in which the position of the double bond is unspecified.

   

(9R,10S)-9,10-Epoxy-18-hydroxyoctadecanoate

(9R,10S)-9,10-Epoxy-18-hydroxyoctadecanoate

C18H33O4 (313.2378718)


A 9,10-epoxy-18-hydroxyoctadecanoate that is the conjugate base of (9R,10S)-9,10-epoxy-18-hydroxyoctadecanoic acid arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

O-[(4Z)-decenoyl]carnitine

O-[(4Z)-decenoyl]carnitine

C17H31NO4 (313.2252966)


An O-decenoylcarnitine having (4Z)-decenoyl as the acyl substituent.

   
   
   
   

Zenidolol (hydrochloride)

Zenidolol (hydrochloride)

C17H28ClNO2 (313.18084580000004)


Zenidolol (ICI-118551) hydrochloride is a highly selective β2 adrenergic receptor antagonist, with Kis of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.

   

n-{[8,11-bis(prop-2-en-1-yl)-1,7-diazatetracyclo[7.2.1.0²,⁷.0⁶,¹¹]dodecan-5-ylidene]methyl}ethanimidic acid

n-{[8,11-bis(prop-2-en-1-yl)-1,7-diazatetracyclo[7.2.1.0²,⁷.0⁶,¹¹]dodecan-5-ylidene]methyl}ethanimidic acid

C19H27N3O (313.2154012)


   

(3s,6r)-5-hydroxy-3-(1h-indol-3-ylmethyl)-1-methyl-6-(2-methylpropyl)-3,6-dihydropyrazin-2-one

(3s,6r)-5-hydroxy-3-(1h-indol-3-ylmethyl)-1-methyl-6-(2-methylpropyl)-3,6-dihydropyrazin-2-one

C18H23N3O2 (313.1790178)


   

hexahydro-1h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-(2-methylpropyl)pentanoate

hexahydro-1h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-(2-methylpropyl)pentanoate

C17H31NO4 (313.2252966)


   

(7as)-1-({[(2r)-2-hydroxy-2-[(1r)-1-methoxyethyl]-3-methylbutanoyl]oxy}methyl)-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate

(7as)-1-({[(2r)-2-hydroxy-2-[(1r)-1-methoxyethyl]-3-methylbutanoyl]oxy}methyl)-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate

C16H27NO5 (313.1889132)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol

C20H27NO2 (313.2041682)


   

12,13-dihydroxy-13-(3-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one

12,13-dihydroxy-13-(3-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one

C17H19N3O3 (313.1426344)


   

5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,17-diol

5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,17-diol

C20H27NO2 (313.2041682)


   

(1s,2r,5s,8r,9s,11r,13r,14s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13-diol

(1s,2r,5s,8r,9s,11r,13r,14s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13-diol

C20H27NO2 (313.2041682)


   

(1s,5s,8r,9s,11r,13s,14s,17r,18r)-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,17-diol

(1s,5s,8r,9s,11r,13s,14s,17r,18r)-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,17-diol

C20H27NO2 (313.2041682)


   

(8s,12r,13s)-12,13-dihydroxy-13-(1-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one

(8s,12r,13s)-12,13-dihydroxy-13-(1-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one

C17H19N3O3 (313.1426344)


   

5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,18-diol

5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,18-diol

C20H27NO2 (313.2041682)


   

(2e,4e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,4-dien-1-one

(2e,4e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,4-dien-1-one

C19H23NO3 (313.16778480000005)


   

(1r,3s,5r,8r,9s,11r,13r,14s,16s,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol

(1r,3s,5r,8r,9s,11r,13r,14s,16s,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol

C20H27NO2 (313.2041682)


   

(2e,6e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one

(2e,6e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one

C19H23NO3 (313.16778480000005)


   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate

C16H27NO5 (313.1889132)


   

1- [α-(1- adamantyl)]- phenyl thiosemicarbazide

NA

C18H23N3S (313.16125980000004)


{"Ingredient_id": "HBIN002265","Ingredient_name": "1- [\u03b1-(1- adamantyl)]- phenyl thiosemicarbazide","Alias": "NA","Ingredient_formula": "C18H23N3S","Ingredient_Smile": "C1C2CC3CC1CC(C2)(C3)C(=NNC(=S)N)C4=CC=CC=C4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "35120","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

2-(decan-9-one)-n-methyl-4-quinolone

NA

C20H27NO2 (313.2041682)


{"Ingredient_id": "HBIN005514","Ingredient_name": "2-(decan-9-one)-n-methyl-4-quinolone","Alias": "NA","Ingredient_formula": "C20H27NO2","Ingredient_Smile": "CC(=O)CCCCCCCCC1=CC(=O)C2=CC=CC=C2N1C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4835","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

3-epischelhammericine

NA

C19H23NO3 (313.16778480000005)


{"Ingredient_id": "HBIN008501","Ingredient_name": "3-epischelhammericine","Alias": "NA","Ingredient_formula": "C19H23NO3","Ingredient_Smile": "COC1CC=C2CCN3C2(C1)C4=CC5=C(C=C4CCC3)OCO5","Ingredient_weight": "313.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7013","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "296196","DrugBank_id": "NA"}

   

3-epishelhammericine

NA

C19H23NO3 (313.16778480000005)


{"Ingredient_id": "HBIN008502","Ingredient_name": "3-epishelhammericine","Alias": "NA","Ingredient_formula": "C19H23NO3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25791","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

amuronine

NA

C19H23NO3 (313.16778480000005)


{"Ingredient_id": "HBIN015931","Ingredient_name": "amuronine","Alias": "NA","Ingredient_formula": "C19H23NO3","Ingredient_Smile": "CN1CCC2=CC(=C(C3=C2C1CC34CCC(=O)C=C4)OC)OC","Ingredient_weight": "313.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1101","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "12306126","DrugBank_id": "NA"}

   

(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate

(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate

C16H27NO5 (313.1889132)


   

(1s,20s)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene

(1s,20s)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene

C19H23NO3 (313.16778480000005)


   

(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 2-hydroxy-2-(1-hydroxyethyl)-4-methylpentanoate

(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 2-hydroxy-2-(1-hydroxyethyl)-4-methylpentanoate

C16H27NO5 (313.1889132)


   

20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene

20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene

C19H23NO3 (313.16778480000005)


   

(1s,5s,8r,9s,11r,14s,16s,17s,18r,19s)-5-(hydroxymethyl)-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-ol

(1s,5s,8r,9s,11r,14s,16s,17s,18r,19s)-5-(hydroxymethyl)-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-ol

C20H27NO2 (313.2041682)


   

(5r,9s,11s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-diol

(5r,9s,11s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-diol

C20H27NO2 (313.2041682)


   

3-({[(1z)-6-[(1e,3e)-hepta-1,3-dien-1-yl]-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one

3-({[(1z)-6-[(1e,3e)-hepta-1,3-dien-1-yl]-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one

C19H23NO3 (313.16778480000005)


   

4,15-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-3-ol

4,15-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-3-ol

C19H23NO3 (313.16778480000005)


   

(1r,3s,5s,8r,9s,11r,13r,14s,16s,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol

(1r,3s,5s,8r,9s,11r,13r,14s,16s,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol

C20H27NO2 (313.2041682)


   

5-hydroxy-3-(1h-indol-3-ylmethyl)-1-methyl-6-(2-methylpropyl)-3,6-dihydropyrazin-2-one

5-hydroxy-3-(1h-indol-3-ylmethyl)-1-methyl-6-(2-methylpropyl)-3,6-dihydropyrazin-2-one

C18H23N3O2 (313.1790178)


   

1-{2,4-dihydroxy-4-isopropyl-6-oxa-3-azabicyclo[3.1.0]hex-2-en-1-yl}-2-hydroxy-2-methyloctan-1-one

1-{2,4-dihydroxy-4-isopropyl-6-oxa-3-azabicyclo[3.1.0]hex-2-en-1-yl}-2-hydroxy-2-methyloctan-1-one

C16H27NO5 (313.1889132)


   

3-[(3r,9s,9ar)-9-hydroxy-2-oxo-octahydroquinolizin-3-yl]quinazolin-4-one

3-[(3r,9s,9ar)-9-hydroxy-2-oxo-octahydroquinolizin-3-yl]quinazolin-4-one

C17H19N3O3 (313.1426344)


   

4-hydroxy-2-[(4z)-undec-4-en-1-yl]quinolin-1-ium-1-olate

4-hydroxy-2-[(4z)-undec-4-en-1-yl]quinolin-1-ium-1-olate

C20H27NO2 (313.2041682)


   

(1s,12s,14r)-9-methoxy-4-(prop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol

(1s,12s,14r)-9-methoxy-4-(prop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol

C19H23NO3 (313.16778480000005)


   

4-hydroxy-2-(undec-4-en-1-yl)quinolin-1-ium-1-olate

4-hydroxy-2-(undec-4-en-1-yl)quinolin-1-ium-1-olate

C20H27NO2 (313.2041682)


   

(1s,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene

(1s,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene

C19H23NO3 (313.16778480000005)


   

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,4-dien-1-one

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,4-dien-1-one

C19H23NO3 (313.16778480000005)


   

6-hydroxy-4-[(2r,3r)-2-hydroxy-3-[(2s,3s)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-3-methoxypropyl]-4,5-dihydro-3h-pyridin-2-one

6-hydroxy-4-[(2r,3r)-2-hydroxy-3-[(2s,3s)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-3-methoxypropyl]-4,5-dihydro-3h-pyridin-2-one

C15H23NO6 (313.1525298)


   

(1s,17r,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene

(1s,17r,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene

C19H23NO3 (313.16778480000005)


   

(1r)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline

(1r)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline

C19H23NO3 (313.16778480000005)


   

1-[(4-hydroxyphenyl)methyl]-6-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-7-olate

1-[(4-hydroxyphenyl)methyl]-6-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-7-olate

C19H23NO3 (313.16778480000005)


   

(1s,17s,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene

(1s,17s,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene

C19H23NO3 (313.16778480000005)


   

4-{[(1s)-7,8-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenol

4-{[(1s)-7,8-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenol

C19H23NO3 (313.16778480000005)


   

(5r)-3-({[(1z,6s)-6-[(1e,3e)-hepta-1,3-dien-1-yl]-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one

(5r)-3-({[(1z,6s)-6-[(1e,3e)-hepta-1,3-dien-1-yl]-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one

C19H23NO3 (313.16778480000005)


   

n-[9-(hex-2-en-1-yl)-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid

n-[9-(hex-2-en-1-yl)-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid

C19H27N3O (313.2154012)


   

(8s,12s,13s)-12,13-dihydroxy-13-(3-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one

(8s,12s,13s)-12,13-dihydroxy-13-(3-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one

C17H19N3O3 (313.1426344)


   

7,8,11-trimethoxy-2h,4h,5h,10h,11h-indolo[7a,1-a]isoquinoline

7,8,11-trimethoxy-2h,4h,5h,10h,11h-indolo[7a,1-a]isoquinoline

C19H23NO3 (313.16778480000005)


   

(1s,4's)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one

(1s,4's)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one

C19H23NO3 (313.16778480000005)


   

(1s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one

(1s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one

C19H23NO3 (313.16778480000005)


   

(2s,3s,4r)-3-methyl-2-[(1e,3e)-4-phenylbuta-1,3-dien-1-yl]piperidin-4-yl 2-methylpropanoate

(2s,3s,4r)-3-methyl-2-[(1e,3e)-4-phenylbuta-1,3-dien-1-yl]piperidin-4-yl 2-methylpropanoate

C20H27NO2 (313.2041682)


   

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one

C19H23NO3 (313.16778480000005)


   

(1s)-7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol

(1s)-7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol

C19H23NO3 (313.16778480000005)


   

5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-(1-methoxyethyl)-3-methylbutanoate

5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-(1-methoxyethyl)-3-methylbutanoate

C16H27NO5 (313.1889132)


   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate

C16H27NO5 (313.1889132)


   

4,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2(7),3,5,13,15-hexaen-3-ol

4,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2(7),3,5,13,15-hexaen-3-ol

C19H23NO3 (313.16778480000005)


   

1-[2-(diethylamino)ethyl]-4-methoxy-9h-pyrido[3,4-b]indol-8-ol

1-[2-(diethylamino)ethyl]-4-methoxy-9h-pyrido[3,4-b]indol-8-ol

C18H23N3O2 (313.1790178)


   

[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r,3r)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r,3r)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate

C16H27NO5 (313.1889132)


   

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one

C19H23NO3 (313.16778480000005)


   

(1r,5s,8r,9s,11r,14s,16r,17r,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-16,19-diol

(1r,5s,8r,9s,11r,14s,16r,17r,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-16,19-diol

C20H27NO2 (313.2041682)


   

12,13-dihydroxy-13-(1-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one

12,13-dihydroxy-13-(1-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one

C17H19N3O3 (313.1426344)


   

(1s,5s,8r,9s,11r,13r,14r,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol

(1s,5s,8r,9s,11r,13r,14r,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol

C20H27NO2 (313.2041682)


   

7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate

7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate

C16H27NO5 (313.1889132)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol

C20H27NO2 (313.2041682)


   

6,8-dimethoxy-9-(methylamino)-2-(prop-1-en-2-yl)-1h,2h,3h,9h-cyclopenta[b]naphthalen-4-one

6,8-dimethoxy-9-(methylamino)-2-(prop-1-en-2-yl)-1h,2h,3h,9h-cyclopenta[b]naphthalen-4-one

C19H23NO3 (313.16778480000005)


   

(1s,5r,8r,9s,11r,13r,14r,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol

(1s,5r,8r,9s,11r,13r,14r,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol

C20H27NO2 (313.2041682)


   

3-({[6-(hepta-1,3-dien-1-yl)-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one

3-({[6-(hepta-1,3-dien-1-yl)-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one

C19H23NO3 (313.16778480000005)


   

(1r,5r,8r,9s,11r,14s,16r,17r,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-16,19-diol

(1r,5r,8r,9s,11r,14s,16r,17r,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-16,19-diol

C20H27NO2 (313.2041682)


   

2-(10-oxoundecyl)-1h-quinolin-4-one

2-(10-oxoundecyl)-1h-quinolin-4-one

C20H27NO2 (313.2041682)


   

20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene

20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene

C19H23NO3 (313.16778480000005)


   

(1s)-1-[2-(4-hydroxyphenyl)ethyl]-7-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol

(1s)-1-[2-(4-hydroxyphenyl)ethyl]-7-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol

C19H23NO3 (313.16778480000005)


   
   

(1r)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

(1r)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

C19H23NO3 (313.16778480000005)


   

n-[(1s,9s,10r)-9-[(2z)-hex-2-en-1-yl]-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid

n-[(1s,9s,10r)-9-[(2z)-hex-2-en-1-yl]-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid

C19H27N3O (313.2154012)


   

(1s)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline

(1s)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline

C19H23NO3 (313.16778480000005)


   

1-[(4-hydroxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-8-olate

1-[(4-hydroxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-8-olate

C19H23NO3 (313.16778480000005)


   

n-[(1s,9r,10r)-9-[(2z)-hex-2-en-1-yl]-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid

n-[(1s,9r,10r)-9-[(2z)-hex-2-en-1-yl]-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid

C19H27N3O (313.2154012)


   

n-{[(5e)-8,11-bis(prop-2-en-1-yl)-1,7-diazatetracyclo[7.2.1.0²,⁷.0⁶,¹¹]dodecan-5-ylidene]methyl}ethanimidic acid

n-{[(5e)-8,11-bis(prop-2-en-1-yl)-1,7-diazatetracyclo[7.2.1.0²,⁷.0⁶,¹¹]dodecan-5-ylidene]methyl}ethanimidic acid

C19H27N3O (313.2154012)


   

n-(5-carbamimidamido-1-oxopentan-2-yl)-2-[(1-hydroxyethylidene)amino]-4-methylpentanimidic acid

n-(5-carbamimidamido-1-oxopentan-2-yl)-2-[(1-hydroxyethylidene)amino]-4-methylpentanimidic acid

C14H27N5O3 (313.2113792)


   

(1s)-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-8-olate

(1s)-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-8-olate

C19H23NO3 (313.16778480000005)


   

5-hydroxy-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)pyrrol-2-one

5-hydroxy-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)pyrrol-2-one

C19H23NO3 (313.16778480000005)


   

3-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenol

3-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenol

C19H23NO3 (313.16778480000005)


   

7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol

7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol

C19H23NO3 (313.16778480000005)


   

(7as)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl (2r)-2,3-dihydroxy-2-[(1r)-1-methoxyethyl]-3-methylbutanoate

(7as)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl (2r)-2,3-dihydroxy-2-[(1r)-1-methoxyethyl]-3-methylbutanoate

C16H27NO5 (313.1889132)


   

3-[(4r,9s,9ar)-9-hydroxy-2-oxo-octahydroquinolizin-4-yl]quinazolin-4-one

3-[(4r,9s,9ar)-9-hydroxy-2-oxo-octahydroquinolizin-4-yl]quinazolin-4-one

C17H19N3O3 (313.1426344)


   

(1s,5'r)-12'-hydroxy-11'-methoxy-6'-methyl-6'-azaspiro[cyclohexane-1,2'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(12'),2,9'(13'),10'-tetraen-4-one

(1s,5'r)-12'-hydroxy-11'-methoxy-6'-methyl-6'-azaspiro[cyclohexane-1,2'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(12'),2,9'(13'),10'-tetraen-4-one

C19H23NO3 (313.16778480000005)


   

2-hexyl-3a,4,6-trihydroxy-6-isopropyl-2-methyl-6ah-furo[2,3-c]pyrrol-3-one

2-hexyl-3a,4,6-trihydroxy-6-isopropyl-2-methyl-6ah-furo[2,3-c]pyrrol-3-one

C16H27NO5 (313.1889132)


   

6-hydroxy-4-[2-hydroxy-3-(2-hydroxy-3-methyl-4-methylideneoxolan-2-yl)-3-methoxypropyl]-4,5-dihydro-3h-pyridin-2-one

6-hydroxy-4-[2-hydroxy-3-(2-hydroxy-3-methyl-4-methylideneoxolan-2-yl)-3-methoxypropyl]-4,5-dihydro-3h-pyridin-2-one

C15H23NO6 (313.1525298)


   

(1r,7ar)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate

(1r,7ar)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate

C16H27NO5 (313.1889132)


   

5,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-4-ol

5,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-4-ol

C19H23NO3 (313.16778480000005)


   

(2r,9r)-6,8-dimethoxy-9-(methylamino)-2-(prop-1-en-2-yl)-1h,2h,3h,9h-cyclopenta[b]naphthalen-4-one

(2r,9r)-6,8-dimethoxy-9-(methylamino)-2-(prop-1-en-2-yl)-1h,2h,3h,9h-cyclopenta[b]naphthalen-4-one

C19H23NO3 (313.16778480000005)


   

3-(9-hydroxy-2-oxo-octahydroquinolizin-4-yl)quinazolin-4-one

3-(9-hydroxy-2-oxo-octahydroquinolizin-4-yl)quinazolin-4-one

C17H19N3O3 (313.1426344)


   

(2r)-2-[(4r)-1-(2,4-dihydroxybutyl)-2-iminoimidazolidin-4-yl]-6-methylhept-5-enoic acid

(2r)-2-[(4r)-1-(2,4-dihydroxybutyl)-2-iminoimidazolidin-4-yl]-6-methylhept-5-enoic acid

C15H27N3O4 (313.2001462)


   

[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate

[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate

C16H27NO5 (313.1889132)


   

(2r,3r,12br)-3-ethyl-2-(2-hydroxyethyl)-5-methyl-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

(2r,3r,12br)-3-ethyl-2-(2-hydroxyethyl)-5-methyl-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

[C20H29N2O]+ (313.2279764)


   

(1s,5r,8r,9s,11r,14s,16s,17s,18r,19s)-5-(hydroxymethyl)-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-ol

(1s,5r,8r,9s,11r,14s,16s,17s,18r,19s)-5-(hydroxymethyl)-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-ol

C20H27NO2 (313.2041682)


   

4,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-5-ol

4,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-5-ol

C19H23NO3 (313.16778480000005)


   

9-methoxy-4-(prop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol

9-methoxy-4-(prop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol

C19H23NO3 (313.16778480000005)


   

4-[(7,8-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]phenol

4-[(7,8-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]phenol

C19H23NO3 (313.16778480000005)